Skip to main content

Table 1 Patient characteristics

From: Incidence and predictors of Lhermitte’s sign among patients receiving mediastinal radiation for lymphoma

Characteristic Value or no. of patients (%)
No LS (n = 75) With LSa (n = 31)
Age, years   
  Median (range) 37 (19–73) 32.0 (18–61)
Sex   
  Female 40 (53) 21 (68)
  Male 35 (47) 10 (32)
Ethnicity   
  Caucasian 59 (78.6) 25 (81)
  African-American 4 (5.4) 2 (6)
  Hispanic 10 (13.4) 4 (12)
  Mid-eastern 2 (2.6) 0
Histology   
  Hodgkin lymphoma 56 (75) 26 (84)
  Non-Hodgkin lymphoma 19 (25) 5 (16)
Disease stage   
  I 3 (4) 3 (10)
  II 55 (73.5) 24 (77)
  III 2 (3) 2 (6.5)
  IV 4 (5) 2 (6.5)
  Recurrent 3 (4)  
  Refractory 6 (8)  
  Unknown 2 (3)  
Radiation technique   
  IMRT 71 (95) 29 (94)
  IMRT & 3D AP/PA 3 (4) 1 (3)
  Protons 1 (1) 1 (3)
RT dose, Gy   
  Mean (range) 32.9 (20–46) 33.2 (30.6–46.6)
  ≤30.6 49 (65) 22 (71)
  >30.6 26 (35) 9 (29)
  30–36 10 (13) 2 (6.5)
  36–45 16 (22) 7 (22.5)
Peripheral neuropathyb   
  Yes 35 (47) 16 (52)
  No 39 (52) 14 (45)
  Unknown 1 (1) 1 (3)
Bleomycin toxicityb   
  Yes 62 (83) 7 (23)
  No 3 (4) 24 (77)
Decreased lung functionc   
  Yes 10 (13) 11 (35)
  No 65 (87) 20 (65)
  1. Abbreviations: IMRT, intensity-modulated radiation therapy; 3D AP/PA, three-dimensional conformal radiation therapy with anteroposterior/posteroanterior fields
  2. aLS at some time during follow-up
  3. bAfter chemotherapy but before radiation therapy
  4. cOut of the 106 patients pulmonary function tests were performed in only 43 patients